Clinical trials: flow cytometry
Coronavirus Disease 2019 (COVID-19)
Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19
SENTAD-COVID Study is an adaptive, prospective, multicentric, open-label, and randomized controlled clinical trial involving hospitalized adult patients with confirmed coronavirus disease 2019 (COVID-19) infection during the…
- Trial name
- SENTAD-COVID (NCT04473170)
- Testing
- Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC), COVID-19 standard care
- Where
- United Arab Emirates
- Volunteers
- 146 people
- Sponsor
- Abu Dhabi Stem Cells Center
Multiple Myeloma
Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
Explore stem cell collection with or without bortezomib with in-vivo purging in multiple myeloma.
- Trial name
- NCT02703779
- Testing
- Bortezomib, Granulocyte colony-stimulating factor (G-CSF), Mozobil
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Siddhartha Ganguly
Leukemia, Myelodysplastic Syndromes
Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898118
- Testing
- polymerase chain reaction, flow cytometry, laboratory biomarker analysis
- Where
- 10 sites in Austria, Belgium and 7 more
- Volunteers
- 125 people
- Sponsor
- European Working Group of MDS in Childhood
Lymphoma
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00513188
- Testing
- denileukin diftitox, cyclophosphamide, cytarabine
- Where
- United States
- Sponsor
- University of Miami
Non-Small Cell Lung Cancer, Lung Adenocarcinoma
Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC
The goal of this observational study is to explore whether changes in peripheral blood effector tumor antigen-specific T cells (ETASTs) can predict treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC)…
- Conditions
- Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT07392073
- Testing
- Circulating Tumor-Specific T Cell Nanodetection Technology (CTT-NanoDT)
- Volunteers
- 80 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Myelodysplastic Syndromes
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy Study
Myelodysplastic syndromes (MDS) are clonal bone marrow neoplasms characterized by dysplasia and ineffective hematopoiesis leading to peripheral blood cytopenias, with an increased risk of progression to acute myeloid leukemia.
- Trial name
- MPO-MDS-Valid (NCT05175469)
- Testing
- Flow cytometric analysis of neutrophil myeloperoxidase expression
- Where
- 8 sites in France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Grenoble
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pancreatic Diseases
Targeting Pathogenic Myelopoiesis in Pancreatic Cancer
This prospective observational study aims to investigate pathogenic myelopoiesis in patients with pancreatic ductal adenocarcinoma (PDAC) and to characterize the systemic immune alterations associated with tumor-related…
- Trial name
- PaMPa (NCT07765316)
- Volunteers
- 100 people
- Sponsor
- IRCCS San Raffaele
Melanoma, Circulating Tumor Cells
In Vivo Liquid Biopsy of Melanoma (Cytophone)
The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body.
- Conditions
- Melanoma, Circulating Tumor Cells, Metastatic Melanoma, Diagnosis
- Trial name
- Cytophone (NCT06488365)
- Testing
- Cytophone
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Cytoastra
Childhood-onset Systemic Lupus Erythematosus
Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE
This prospective observational study aims to characterize the peripheral immune landscape of pediatric patients with childhood-onset systemic lupus erythematosus ( cSLE) who are receiving CD3×CD19 bispecific T-cell engager (BiTE)…
- Trial name
- BiTE-cSLE-IP (NCT07352332)
- Where
- China
- Volunteers
- 6 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Brain and Central Nervous System Tumors
Study of Tissue and Blood Samples From Patients With High-Grade Glioma
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01004887
- Testing
- diagnostic laboratory biomarker analysis
- Where
- 110 sites in United States
- Volunteers
- 631 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Tuberculosis
Tuberculosis Diagnosis by Flow Cytometry
Tuberculosis and HIV continue to be major public health problems in resource constrained settings like Zambia. Zambia is among the top 30 highest burden countries globally.
- Trial name
- NCT03639038
- Where
- Zambia
- Sponsor
- University of Alabama at Birmingham
HIV Infection, Tuberculosis Infection
Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
The role of miRNAs in HIV disease is yet to be completely defined. Host miRNAs target certain HIV genes, thus can affect HIV replication and participate in viral control.
- Trial name
- miRNA (NCT03941210)
- Testing
- Detection of molecular Biomarkers
- Where
- Cambodia
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Lymphoma
RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
RATIONALE: Immunotoxins, such as RFT5-dgA immunotoxin (also called anti-CD25 immunotoxin IMTOX25), can find certain cancer cells and kill them without harming normal cells.
- Trial name
- NCT00667017
- Testing
- RFT5-dgA immunotoxin, fluorescence activated cell sorting, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Lymphoproliferative Diseases (CLPD)
Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer
Multi-site, prospective performance study to determine equivalency between the investigational CLPD Limited Panel on the FACSLyric system versus the final clinical diagnosis.
- Trial name
- NCT05032313
- Testing
- IUO CLPD Limited Panel
- Where
- 6 sites in United States, Portugal and 3 more
- Volunteers
- 371 people
- Sponsor
- Becton, Dickinson and Company
Lymphoma, Hemophagocytic Lymphohistiocytoses
Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas
The goal of this study is to explore the associations between T cell activation and the occurrence of hemophagocytic lymphohistiocytosis (HLH) in patients with newly diagnosed lymphomas.
- Trial name
- LA-HLH (NCT06585124)
- Testing
- Flow Cytometry
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
RATIONALE: Biological therapies, such as fusion protein cytokine therapy, may stimulate the immune system in different ways and stop cancer cells from growing.
- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma
- Trial name
- NCT00720135
- Testing
- DI-Leu16-IL2 immunocytokine, rituximab, flow cytometry
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Rectal Cancer
IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment.
Background The current management on rectal cancer based on TNM staging has some limitations. In locally advanced rectal cancer after neoadjuvant therapy the persistence of a complete response to therapy cannot be accurately…
- Trial name
- IMMUNOREACT2 (NCT04917263)
- Testing
- Immunohistochemistry, Flow citometry, Trascriptome analysis
- Where
- Italy
- Volunteers
- 544 people
- Sponsor
- University of Padova
Colorectal Cancer
T Helper Cytokines in End Stage Colorectal Cancers
Colorectal cancers are the third most common type of cancer in the world. Peritoneal carcinomatosis and intraabdominal acid development occur in advanced stages of colorectal cancers.
- Trial name
- NCT04540146
- Testing
- Flow-Cytometric analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Istanbul Training and Research Hospital
Increased Drug Resistance
Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Population
The primary objective of this prospective clinical registry is to determine the prevalence and level of thienopyridine resistance seen in a population undergoing contemporary percutaneous coronary intervention (PCI) or coronary…
- Trial name
- VASP (NCT01408927)
- Testing
- Thienopyridine resistance testing, Aspirin resistance testing, Genetic polymorphism assessment
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Medstar Health Research Institute